UOC
ZYNE

UBS O'Connor’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

UBS O'Connor’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-63,614
Closed -$189K – 164
2018
Q4 		$189K Hold
63,614
– – 0.01% 213
2018
Q3 		$519K Buy
+63,614
New +$488K 0.01% 242

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Campbell Capital Management Miami, Florida $279M AUM 49.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return

UBS O'Connor's ZYNE Position: Q1 2019 in Review

UBS O'Connor sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2019, closing a stake of 63,614 shares — an estimated $189K sold.

UBS O'Connor first reported a position in ZYNE in Q3 2018 and held it in 2 quarters. The position peaked at $519K in Q3 2018. 61 funds tracked by Wall St. Rank hold ZYNE as of Q1 2019.

  • UBS O'Connor reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2019 after selling out during the quarter.
  • UBS O'Connor sold 63,614 Zynerba Pharmaceuticals, Inc shares in Q1 2019, an estimated $189K.
  • UBS O'Connor first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2018 and held it in 2 quarters.
  • UBS O'Connor's Zynerba Pharmaceuticals, Inc position peaked at $519K in Q3 2018.
  • 61 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2019.

Based on UBS O'Connor's 13F filing for Q1 2019, filed 13 May 2019.